Firebrick Pharma Ltd
Firebrick Pharma Limited engages in the development and commercialization of povidone-iodine (PVP-I) products under the Nasodine brand in Asia, North America, Europe, and internationally. It offers nasal spray PVP-I products for the treatment of common cold. The company was incorporated in 2012 and is based in Melbourne, Australia.
Firebrick Pharma Ltd (FRE) - Net Assets
Latest net assets as of June 2025: AU$1.56 Million AUD
Based on the latest financial reports, Firebrick Pharma Ltd (FRE) has net assets worth AU$1.56 Million AUD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$1.83 Million) and total liabilities (AU$271.28K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | AU$1.56 Million |
| % of Total Assets | 85.16% |
| Annual Growth Rate | 6.3% |
| 5-Year Change | -86.53% |
| 10-Year Change | N/A |
| Growth Volatility | 1080.4 |
Firebrick Pharma Ltd - Net Assets Trend (2019–2025)
This chart illustrates how Firebrick Pharma Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Firebrick Pharma Ltd (2019–2025)
The table below shows the annual net assets of Firebrick Pharma Ltd from 2019 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | AU$1.56 Million | -26.42% |
| 2024-06-30 | AU$2.12 Million | -14.57% |
| 2023-06-30 | AU$2.48 Million | -70.09% |
| 2022-06-30 | AU$8.28 Million | -28.34% |
| 2021-06-30 | AU$11.55 Million | +2857.87% |
| 2020-06-30 | AU$390.60K | -63.79% |
| 2019-06-30 | AU$1.08 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Firebrick Pharma Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1769098500.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | AU$19.77 Million | 1270.55% |
| Other Comprehensive Income | AU$446.57K | 28.69% |
| Other Components | AU$122.55K | 7.87% |
| Total Equity | AU$1.56 Million | 100.00% |
Firebrick Pharma Ltd Competitors by Market Cap
The table below lists competitors of Firebrick Pharma Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Olympia Industries Bhd
KLSE:3018
|
$4.12 Million |
|
Lagnam Spintex Limited
NSE:LAGNAM
|
$4.12 Million |
|
Country Heights Holdings Bhd
KLSE:5738
|
$4.13 Million |
|
Acco Group Holdings Limited Ordinary Shares
NASDAQ:ACCL
|
$4.13 Million |
|
Norwest Minerals Ltd
AU:NWM
|
$4.12 Million |
|
Realfiction Holding AB
ST:REALFI
|
$4.12 Million |
|
Trisula International Tbk
JK:TRIS
|
$4.12 Million |
|
EL. D. Mouzakis S.A
AT:MOYZK
|
$4.12 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Firebrick Pharma Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,115,272 to 1,556,372, a change of -558,900 (-26.4%).
- Net loss of 2,634,428 reduced equity.
- Share repurchases of 27,395 reduced equity.
- New share issuances of 1,925,602 increased equity.
- Other comprehensive income decreased equity by 297,522.
- Other factors increased equity by 474,843.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | AU$-2.63 Million | -169.27% |
| Share Repurchases | AU$27.39K | -1.76% |
| Share Issuances | AU$1.93 Million | +123.72% |
| Other Comprehensive Income | AU$-297.52K | -19.12% |
| Other Changes | AU$474.84K | +30.51% |
| Total Change | AU$- | -26.42% |
Book Value vs Market Value Analysis
This analysis compares Firebrick Pharma Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 7.84x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 9.08x to 7.84x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-06-30 | AU$0.01 | AU$0.06 | x |
| 2020-06-30 | AU$0.00 | AU$0.06 | x |
| 2021-06-30 | AU$0.07 | AU$0.06 | x |
| 2022-06-30 | AU$0.05 | AU$0.06 | x |
| 2023-06-30 | AU$0.01 | AU$0.06 | x |
| 2024-06-30 | AU$0.01 | AU$0.06 | x |
| 2025-06-30 | AU$0.01 | AU$0.06 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Firebrick Pharma Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -169.27%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -897.83%
- • Asset Turnover: 0.16x
- • Equity Multiplier: 1.17x
- Recent ROE (-169.27%) is below the historical average (-145.34%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -67.23% | 0.00% | 0.00x | 1.09x | AU$-833.14K |
| 2020 | -383.64% | -294.41% | 0.78x | 1.68x | AU$-1.54 Million |
| 2021 | -21.11% | -577.97% | 0.04x | 1.02x | AU$-3.59 Million |
| 2022 | -45.85% | -92054.07% | 0.00x | 1.05x | AU$-4.62 Million |
| 2023 | -274.72% | -819526.75% | 0.00x | 1.20x | AU$-7.05 Million |
| 2024 | -55.59% | -8097.12% | 0.01x | 1.14x | AU$-1.39 Million |
| 2025 | -169.27% | -897.83% | 0.16x | 1.17x | AU$-2.79 Million |
Industry Comparison
This section compares Firebrick Pharma Ltd's net assets metrics with peer companies in the Drug Manufacturers - General industry.
No peer company data available for comparison.